Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

Recruiting

Phase 2

rF1V-1018Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

Sponsor:

Dynavax Technologies Corporation

Code:

NCT07207408

Conditions

Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Accepted

Interventions

rF1V-1018

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by Dynavax Technologies Corporation on 2025-10-06.